1. Bonadonna G, Zambetti M, Valagussa P (1995) Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. JAMA 273:542–547
2. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439
3. Dang CT, Moynahan ME, Dickler MN, Seidman A, Fornier M, Theodoulou M, Lake D, Hurria A, Norton L, Hudis CA (2003) Phase II study of dose-dense (DD) 5-fluorouracil, epirubicin, and cyclophosphamide followed by alternating weekly paclitaxel (P) and docetaxel (D) in high-risk node-positive (N+) breast cancer: Feasibility and efficacy (abstract 46). Proc Am Soc Clin Oncol 22:12A
4. Fisher B, Bauer M, Wickerham OL, Redmond CK, Fisher ER, Cruz AB, Foster R, Gardner B, Lerner H, Margolese R (1983) Relation of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 52:1551–1557
5. Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D’Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C (2001) Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive primary breast cancer. Clin Cancer Res 7:3934–3941